Monitoring Drug Therapy
Course Overview
Morning sessions will provide state-of-the-art updates on immunosuppressive therapy, anticonvulsant therapy, drug therapy for patients with liver disease, and drug therapy for patients with renal disease, with an emphasis on both pharmacodynamic (PD) and pharmacokinetic (PK) monitoring, accompanied by a panel discussion to probe deeper into areas of interest. Afternoon sessions will cover topics such as monitoring trilostane therapy, monitoring mineralocorticoid therapy in patients with Addison’s disease, antimicrobial therapy and avoiding antimicrobial resistance, and pharmacogenomics, again accompanied by a panel discussion. Presenters will have focused research expertise and clinical experience in monitoring drug therapy, and attendees will be exposed to deep and up-to-the minute information on the practical aspects of advanced therapeutic drug monitoring.
This course was made possible thanks to the generous support of IDEXX and Dechr.
Who Should Attend
- ACVIM Diplomates and Candidates
- European affiliate Diplomates and Candidates
- ECEIM Diplomates and Candidates
- ECVN Diplomates and Candidates
Agenda
Document
By the end of the course, you will be able to:
- Apply PK and PD principles to their patients in order to individualize drug therapy.
- Adjust anticonvulsant and immunosuppressive therapy based on therapeutic drug monitoring.
- Make rational therapeutic decisions in patients with hepatic and renal disease.
- Utilize pharmacodynamic monitoring principles to adjust therapy in patients with Cushing’s and Addison’s disease.
- Administer and monitor antimicrobial therapy with a focus on both efficacy and avoidance of antimicrobial resistance.
- Understand the impact of patient pharmacogenomic variability on drug therapy.
Cost
| Category | Price |
|---|---|
| ACVIM Diplomate; European Partner Diplomate | $350 |
| ACVIM Candidate; European Partner Resident | $175 |
| Nonmember Diplomate, VCS Member | $475 |
| Nonmember Candidate | $240 |
CE Credits
This program will be submitted (but not yet approved) for 7.5 hours of live, seminar/lecture continuing education credit in jurisdictions which recognize AAVSB RACE-approval.